Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-07T09:51:15.506Z Has data issue: false hasContentIssue false

Comparison of Val66met Polymorphism of BDNF gene in patients of bipolar disorder and healthy controls.

Published online by Cambridge University Press:  27 August 2024

M. Srikantamurthy*
Affiliation:
1Department of psychiatry, Orygen youth health, Melbourne, Australia
S. Moirangathem
Affiliation:
2Department of psychiatry
B. Viswanath
Affiliation:
2Department of psychiatry
M. Purushottam
Affiliation:
3Department of molecular genetics, National Institute of Mental Health and Neurosciences, Bangalore, India
S. Jain
Affiliation:
2Department of psychiatry
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

The study aims to explore the utility of BDNF Val66Met polymorphism as a potential biomarker in Indian bipolar disorder patients and its correlation with clinical characteristics.

Objectives

Genotyping Val66Met in BDNF gene

Exploring its association with bipolar disorder (BD).

Methods

150 consenting BD patients and matched controls were recruited using a case-control study design. BD severity was assessed using Young’s mania rating scale and the Clinical Global Impression - Severity (CGI-S) scale. BDNF Val66Met polymorphism was identified through real-time PCR after DNA extraction. Data was tested for normal distribution. Genotype frequencies between two groups were compared and the Hardy-Weinberg equilibrium assumptions were tested using Chi-Square tests. Clinical-genotypic associations were explored using the Kruskal-Wallis test and confirmed using hierarchical regression.

Results

Our sample had more males (60%) than females (40%) with mean age of 35.05 years. Most patients had established bipolar disorder and were severely ill (CGI: 38.75, YMRS). Val66Met SNP genotype frequency differed significantly between cases and controls. Val66Val genotype and Val allele were higher in cases. Results consistent with Hardy-Weinberg equilibrium.Table 1.

Genotype frequencies of BDNF (rs6265) in cases and controls

GENOTYPE
CCCTTT
CASES94(62.6%)47(31.3%)9(6%)
CONTROL71(47.3%)69(46%)10(6.6%)
CHI-SQUARE- 7.431DF(Degree of freedom) - 2p-value- 0.024
Table 2.

Dominant genotype frequencies in cases and controls

DOMINANT GENOTYPE
CCCT+TT
CASES94(62.6%)56(37.3%)
CONTROLS71(47.3%)79(52.6)
CHI-SQUARE-7.125DF(Degree of freedom)-1p-value-0.007
Table 3.

Allelic frequencies of BDNF (rs6265) in BD cases and healthy controls

ALLELIC VARIATION
CT
CASES235(78.3%)65(21.6%)
CONTROLS211(70.3%)89(29.6%)
CHI-SQUARE-5.032DF(Degree of freedom)-1p-value- 0.024

Conclusions

Our study found that Val66Val genotype and Val allele were higher in cases and could be a potential biomarker for bipolar disorder (BD), which is consistent with previous research conducted on the European population. However, further investigations are required to gain a more comprehensive understanding of its impact on BD, including its association with serum BDNF levels, treatment outcomes, and a more diverse study population.

Disclosure of Interest

None Declared

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.